Delayed
Deutsche Boerse AG
12:53:45 29/11/2023 pm IST
|
5-day change
|
1st Jan Change
|
0.292
EUR
|
+4.29%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Capitalization
1 |
9.026
|
22.82
|
3.892
|
Enterprise Value (EV)
1 |
-0.4874
|
8.772
|
-4.857
|
P/E ratio
|
-0.77
x
|
-1.34
x
|
-0.14
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
19.9
x
|
25.7
x
|
46.8
x
|
EV / Revenue
|
-1.07
x
|
9.89
x
|
-58.4
x
|
EV / EBITDA
|
-
|
-8,23,776
x
|
2,52,552
x
|
EV / FCF
|
43,199
x
|
-17,31,011
x
|
5,84,341
x
|
FCF Yield
|
0%
|
-0%
|
0%
|
Price to Book
|
2.68
x
|
1.72
x
|
0.74
x
|
Nbr of stocks (in thousands)
|
241
|
1,276
|
2,971
|
Reference price
2 |
37.51
|
17.89
|
1.310
|
Announcement Date
|
23/03/21
|
31/03/22
|
31/03/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.3246
|
0.4538
|
0.8865
|
0.0832
|
EBITDA
|
-
|
-
|
-10.65
|
-19.23
|
EBIT
1 |
-3.645
|
-18.71
|
-10.65
|
-19.24
|
Operating Margin
|
-1,122.63%
|
-4,123.03%
|
-1,201.33%
|
-23,125.86%
|
Earnings before Tax (EBT)
1 |
-3.645
|
-15.08
|
-10.67
|
-19.37
|
Net income
1 |
-3.645
|
-15.12
|
-10.64
|
-19.38
|
Net margin
|
-1,122.68%
|
-3,331.27%
|
-1,200.09%
|
-23,299.05%
|
EPS
|
-
|
-48.60
|
-13.31
|
-9.193
|
Free Cash Flow
|
-
|
-11.28
|
-5.068
|
-8.312
|
FCF margin
|
-
|
-2,486.28%
|
-571.63%
|
-9,992.88%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
23/03/21
|
31/03/22
|
31/03/23
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
---|
Net sales
1 |
0.19
|
0.0832
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.805
|
-3.138
|
-9.404
|
-3.127
|
-3.566
|
-4
|
-3.999
|
Operating Margin
|
-1,476.18%
|
-3,772.76%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/03/22
|
12/05/22
|
11/08/22
|
14/11/22
|
31/03/23
|
15/05/23
|
21/08/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.06
|
9.51
|
14.1
|
8.75
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-11.3
|
-5.07
|
-8.31
|
ROE (net income / shareholders' equity)
|
-
|
-371%
|
-93.4%
|
-209%
|
ROA (Net income/ Total Assets)
|
-
|
-200%
|
-45.1%
|
-85.3%
|
Assets
1 |
-
|
7.574
|
23.6
|
22.71
|
Book Value Per Share
|
-
|
14.00
|
10.40
|
1.760
|
Cash Flow per Share
|
-
|
19.10
|
13.20
|
3.060
|
Capex
|
-
|
-
|
0.02
|
0.01
|
Capex / Sales
|
-
|
-
|
2.01%
|
8.52%
|
Announcement Date
|
30/03/20
|
23/03/21
|
31/03/22
|
31/03/23
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 966K | | +35.14% | 51.51B | | -7.43% | 39.03B | | +34.38% | 38.91B | | -10.62% | 26.68B | | +11.63% | 26.13B | | -17.77% | 19.91B | | +40.52% | 13.71B | | +30.70% | 12.38B | | -3.41% | 11.74B |
Other Biotechnology & Medical Research
|